Authors: Dippel, EJ Kereiakes, DJ Tramuta, DA Broderick, TM Shimshak, TM Roth, EM Hattemer, CR Runyon, JP Whang, DD Schneider, JF Abbottsmith, CW

Citation: Ej. Dippel et al., Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: An algorithm for percutaneous management, CATHET C IN, 52(3), 2001, pp. 279-286

Authors: Kereiakes, DJ Kleiman, NS Fry, E Mwawasi, G Lengerich, R Maresh, K Burkert, ML Aquilina, JW DeLoof, M Broderick, TM Shimshak, TM

Citation: Dj. Kereiakes et al., Dalteparin in combination with abciximab during percutaneous coronary intervention, AM HEART J, 141(3), 2001, pp. 348-352

Authors: Kereiakes, DJ Broderick, TM Abbottsmith, C Shimshak, TM

Citation: Dj. Kereiakes et al., Bleeding risks and vascular complications following abciximab therapy for percutaneous coronary intervention: A new look at an old problem, J INVAS CAR, 12(2), 2000, pp. 95-98

Authors: Kereiakes, DJ Young, J Broderick, TM Shimshak, TM Abbottsmith, CW

Citation: Dj. Kereiakes et al., Therapeutic adjuncts for immediate transfer to the catheterization laboratory in patients with acute coronary syndromes, AM J CARD, 86(12B), 2000, pp. 10M-17M

Authors: Kereiakes, DJ Runyon, JP Broderick, TM Shimshak, TM

Citation: Dj. Kereiakes et al., IIb's are not IIb's, AM J CARD, 85(8A), 2000, pp. 23C-31C

Authors: Kereiakes, DJ Obenchain, RL Barber, BL Smith, A McDonald, M Broderick, TM Runyon, JP Shimshak, TM Schneider, JF Hattemer, CR Roth, EM Whang, DD Cocks, D Abbottsmith, CW

Citation: Dj. Kereiakes et al., Abciximab provides cost-effective survival advantage in high-volume interventional practice, AM HEART J, 140(4), 2000, pp. 603-610